B2M and benign prostatic hyperplasia: Jedinak reported a multimodal biomarker combining three proteins (β2M, PGA3 and MUC3) discovered by proteomic analysis of neat urine with PSA to discriminate BPH and PCa in 173 patients, obtaining an AUC of 0.81 (95% CI 0.74–0.89) [32].